4055 related articles for article (PubMed ID: 24352797)
1. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
James PA; Oparil S; Carter BL; Cushman WC; Dennison-Himmelfarb C; Handler J; Lackland DT; LeFevre ML; MacKenzie TD; Ogedegbe O; Smith SC; Svetkey LP; Taler SJ; Townsend RR; Wright JT; Narva AS; Ortiz E
JAMA; 2014 Feb; 311(5):507-20. PubMed ID: 24352797
[TBL] [Abstract][Full Text] [Related]
2. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
[TBL] [Abstract][Full Text] [Related]
4. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
Hackam DG; Khan NA; Hemmelgarn BR; Rabkin SW; Touyz RM; Campbell NR; Padwal R; Campbell TS; Lindsay MP; Hill MD; Quinn RR; Mahon JL; Herman RJ; Schiffrin EL; Ruzicka M; Larochelle P; Feldman RD; Lebel M; Poirier L; Arnold JM; Moe GW; Howlett JG; Trudeau L; Bacon SL; Petrella RJ; Milot A; Stone JA; Drouin D; Boulanger JM; Sharma M; Hamet P; Fodor G; Dresser GK; Carruthers SG; Pylypchuk G; Burgess ED; Burns KD; Vallée M; Prasad GV; Gilbert RE; Leiter LA; Jones C; Ogilvie RI; Woo V; McFarlane PA; Hegele RA; Tobe SW;
Can J Cardiol; 2010 May; 26(5):249-58. PubMed ID: 20485689
[TBL] [Abstract][Full Text] [Related]
5. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
Chobanian AV; Bakris GL; Black HR; Cushman WC; Green LA; Izzo JL; Jones DW; Materson BJ; Oparil S; Wright JT; Roccella EJ; ;
JAMA; 2003 May; 289(19):2560-72. PubMed ID: 12748199
[TBL] [Abstract][Full Text] [Related]
6. Cochrane in context: pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
[TBL] [Abstract][Full Text] [Related]
7. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
[TBL] [Abstract][Full Text] [Related]
8. Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report.
Colvin CL; King JB; Oparil S; Wright JT; Ogedegbe G; Mohanty A; Hardy ST; Huang L; Hess R; Muntner P; Bress A
JAMA Netw Open; 2020 Nov; 3(11):e2025127. PubMed ID: 33206191
[TBL] [Abstract][Full Text] [Related]
9. Renal protection in hypertensive patients: selection of antihypertensive therapy.
Wenzel RR
Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
[TBL] [Abstract][Full Text] [Related]
10. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.
Khan NA; Hemmelgarn B; Herman RJ; Bell CM; Mahon JL; Leiter LA; Rabkin SW; Hill MD; Padwal R; Touyz RM; Larochelle P; Feldman RD; Schiffrin EL; Campbell NR; Moe G; Prasad R; Arnold MO; Campbell TS; Milot A; Stone JA; Jones C; Ogilvie RI; Hamet P; Fodor G; Carruthers G; Burns KD; Ruzicka M; DeChamplain J; Pylypchuk G; Petrella R; Boulanger JM; Trudeau L; Hegele RA; Woo V; McFarlane P; Vallée M; Howlett J; Bacon SL; Lindsay P; Gilbert RE; Lewanczuk RZ; Tobe S;
Can J Cardiol; 2009 May; 25(5):287-98. PubMed ID: 19417859
[TBL] [Abstract][Full Text] [Related]
11. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
Khan NA; Hemmelgarn B; Herman RJ; Rabkin SW; McAlister FA; Bell CM; Touyz RM; Padwal R; Leiter LA; Mahon JL; Hill MD; Larochelle P; Feldman RD; Schiffrin EL; Campbell NR; Arnold MO; Moe G; Campbell TS; Milot A; Stone JA; Jones C; Ogilvie RI; Hamet P; Fodor G; Carruthers G; Burns KD; Ruzicka M; dechamplain J; Pylypchuk G; Petrella R; Boulanger JM; Trudeau L; Hegele RA; Woo V; McFarlane P; Vallée M; Howlett J; Katzmarzyk P; Tobe S; Lewanczuk RZ;
Can J Cardiol; 2008 Jun; 24(6):465-75. PubMed ID: 18548143
[TBL] [Abstract][Full Text] [Related]
12. Update on the management of hypertension: recent clinical trials and the JNC 7.
Moser M
J Clin Hypertens (Greenwich); 2004 Oct; 6(10 Suppl 2):4-13. PubMed ID: 15470293
[TBL] [Abstract][Full Text] [Related]
13. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
14. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
Khan NA; Hemmelgarn B; Padwal R; Larochelle P; Mahon JL; Lewanczuk RZ; McAlister FA; Rabkin SW; Hill MD; Feldman RD; Schiffrin EL; Campbell NR; Logan AG; Arnold M; Moe G; Campbell TS; Milot A; Stone JA; Jones C; Leiter LA; Ogilvie RI; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; Burns KD; Ruzicka M; deChamplain J; Pylypchuk G; Gledhill N; Petrella R; Boulanger JM; Trudeau L; Hegele RA; Woo V; McFarlane P; Touyz RM; Tobe SW;
Can J Cardiol; 2007 May; 23(7):539-50. PubMed ID: 17534460
[TBL] [Abstract][Full Text] [Related]
15. Hydrochlorothiazide versus calcium channel blockers: what is the best add-on to a renin-angiotensin system blocker for treating hypertension in patients with renal disease?
Lerma EV
Curr Hypertens Rep; 2011 Oct; 13(5):386-95. PubMed ID: 21796332
[TBL] [Abstract][Full Text] [Related]
16. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy.
Khan NA; McAlister FA; Rabkin SW; Padwal R; Feldman RD; Campbell NR; Leiter LA; Lewanczuk RZ; Schiffrin EL; Hill MD; Arnold M; Moe G; Campbell TS; Herbert C; Milot A; Stone JA; Burgess E; Hemmelgarn B; Jones C; Larochelle P; Ogilvie RI; Houlden R; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; Dechamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Tobe S; Touyz RM;
Can J Cardiol; 2006 May; 22(7):583-93. PubMed ID: 16755313
[TBL] [Abstract][Full Text] [Related]
17. Treating essential hypertension. The first choice is usually a thiazide diuretic.
Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125
[TBL] [Abstract][Full Text] [Related]
18. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker?
Riva N; Lip GY
Curr Pharm Des; 2013; 19(21):3753-65. PubMed ID: 23286431
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
